El interés en corto de Oncology Institute da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Oncology Institute. Los datos de interés en corto se actualizan cada dos semanas.

Oncology Institute (NASDAQ:TOI) Bolsa, Informe de interés en corto

Oncology Institute

The Oncology Institute

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.

The Oncology Institute, Inc. - Common Stock

The Oncology Institute Inc

THAI OIL PCL FGN REG SHS by Thai Oil Public Co., Ltd.

Thai Oil PCL

THAI OIL PCL UNSP/ADR by Thai Oil Public Co., Ltd.

TOPICUS COM INC SUB VTG by TOPICUS COM INC.

Topicus com Inc

News

TRNR

Interactive Strength Inc.  Secures $3.6M in 3-Year Notes From Institutional Investor, Following $2.9M Investment

Earnings

VNET

VNET Q4 EPADS $(0.01) Misses $0.03 Estimate, Sales $307.75M Beat $284.88M Estimate

For the full-year 2025, which will set the stage to become a pure-play Power company, we currently expect:
<ul>
<li>Consolidated revenue from continuing operations to grow mid-to-high single digit year-over-year as compared with equivalent revenue of $185.8 million in 2024.</li>
<li>Consolidated gross profit margin from continuing operations between 19.5% to 21.5%, reflecting the fact that we have completed the wind down of Transitional Foundry Services and new generation power products will just begin production in the second half 2025. The equivalent gross profit margin was 21.5% in 2024.</li>
</ul>

Guidance

Magnachip Expects FY25 Revenue Growth From Continuing Operations Of Mid-To-High Single Digit Vs $185.8M YoY

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Buy and maintains $40 price target.

Price Target

Reiteration

Analyst Ratings

DNTH

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

TSLA CLIMBS OVER 14 POINTS AFTER ALERT
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/11205022/Screenshot-2025-03-11-at-4.48.04%E2%80%AFPM-1021x1024.png" alt="" class="wp-image-7659" /></figure>
Tesla, Inc. (TSLA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 09:46 AM on March 11th, a significant trading signal occurred for Tesla, Inc. (TSLA) as it demonstrated a Power Inflow at a price of $222.68. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Tesla&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Tesla&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for TSLA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $222.68. The returns on the High price ($236.94) and Close price ($230.58) after the Power Inflow were respectively 6.4% and 3.5%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. 
Past Performance is Not Indicative of Future Results

Equities

Technicals

Signals

Markets

Trading Ideas

Tesla Stock Pares Early Losses, Rises 6.4% After Key Signal

The company continues to&nbsp;tightly manage its operating expenses and its cash position. The company reaffirms its belief that current cash and investments and other assets are adequate to support continuing operations for the foreseeable future.

AMRN

Amarin Says Continuing To Explore All Strategies To Accelerate Growth In Europe Region

KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.87) by 5.75 percent. This is a 9.52 percent decrease over losses of $(0.84) per share from the same period last year.

KALV

KalVista Pharma Q3 2025 GAAP EPS $(0.92) Misses $(0.87) Estimate, The Company Had Cash, Cash Equivalents And Marketable Securities Of Approximately $253.2M

WIIM

VSTE

Vast Renewables shares are trading higher after the company received up to AUD180M in conditional funding from the Australian Renewable Energy Agency for its Port Augusta clean energy project.

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and raises the price target from $7 to $7.25.

HC Wainwright & Co. Maintains Buy on Endeavour Silver, Raises Price Target to $7.25

For Q1 2025:
<ul>
<li>Consolidated revenue from continuing operations (which includes Power discrete and Power IC businesses, and excludes our former Display business) to be in the range of $42 to $47 million, down 8.9% sequentially due primarily to seasonality, but up 11.5% year-over-year at the mid-point. This compares with equivalent revenue of $48.9 million in Q4 2024 and $39.9 million in Q1 2024.</li>
<li>Consolidated gross profit margin from continuing operations to be in the range of 18.5% to 20.5%, due to the seasonal sequential decline in revenue and the wind down of Transitional Foundry Services impacting fab utilization. This compares with equivalent gross profit margin of 23.2% in Q4 2024 and 17.6% in Q1 2024.</li>
</ul>

Magnachip Expects Q1 Revenue From Continuing Operations Of $42M-$47M, Up 11.5% YoY

Financing

Vast Renewables Limited Receives Up To AUD180M Of Conditional Funding From Australian Renewable Energy Agency For Construction Of Its Port Augusta Utility-Scale Clean Energy Project

Full-Year 2025 Guidance
In 2025, the Company expects to generate Adjusted EBITDA between $1.6 billion and $2.2 billion and Adjusted EBIT between $350 million and $950 million.

ZIM Integrated Shipping Services 2025 Outlook: Expects Adjusted EBITDA Of $1.6B-$2.2B And Adjusted EBIT Of $350M-$950M

Amarin Intends To Effect Ratio Change On ADSs From One ADS Representing One Ordinary Share To New Ratio Of One ADS Representing 20 Ordinary Shares

HC Wainwright &amp; Co. analyst Scott Buck reiterates Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Buy and maintains $26 price target.

HC Wainwright & Co. Reiterates Buy on Redwire, Maintains $26 Price Target

Stock Split

Amarin To Effect An ADS Ratio Change From One ADS Representing One Ordinary Share To One ADS Representing Twenty Ordinary Shares

Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 76.92 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $143.537 million which missed the analyst consensus estimate of $162.060 million by 11.43 percent. This is a 13.18 percent decrease over sales of $165.318 million the same period last year.

Earnings Misses

Solo Brands Q4 2024 Adj. EPS $0.03 Misses $0.11 Estimate, Sales $143.537M Miss $162.060M Estimate

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $1.95 million which beat the analyst consensus estimate of $1.82 million by 7.29 percent. This is a 10.68 percent increase over sales of $1.76 million the same period last year.

NSPR

InspireMD Q4 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $1.95M Beat $1.82M Estimate

Earnings Beats

HBIO

Harvard Bioscience Q4 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $24.556M Beat $24.150M Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Buy and maintains $6 price target.

EVEX

HC Wainwright & Co. Reiterates Buy on Eve Holding, Maintains $6 Price Target

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $62.31 million which beat the analyst consensus estimate of $35.92 million by 73.48 percent. This is a 16.61 percent decrease over sales of $74.71 million the same period last year.

Comments

Oncology Institute

Interés en corto

Oncology Institute (NASDAQ:TOI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL